Sandbox vidit2: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Vidit Bhargava (talk | contribs)
nocaptcha
1,887 edits
No edit summary
Vidit Bhargava (talk | contribs)
nocaptcha
1,887 edits
No edit summary
Line 1: Line 1:
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
|-
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug & Dosage'''
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''[[Loading dose]]''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''[[Maintenance dose]]'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (100 to 400 mg)'''''<BR>''OR''<BR>▸ '''''[[Disopyramide]] (400 to 750 mg)'''''<BR>''OR''<BR> ▸ '''''[[Dofetilide]] (500 to 1000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Flecainide]] (200 to 300 mg)'''''<BR>''OR''<BR>▸ '''''[[Procainamide]] (1000 to 4000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Propafenone]] (450 to 900 mg)'''''<BR>''OR''<BR>▸ '''''[[Quinidine]] (600 to 1500 mg)'''''<BR>''OR''<BR>▸ '''''[[Sotalol]] (160 to 320 mg)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Acute Setting'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control in patients without [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Esmolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''500 mcg/kg IV over 1 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''60 to 200 mcg/kg/min IV'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.15 mg/kg IV''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''2.5 to 5 mg IV bolus over 2 min; up to 3 doses''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''5 to 15 mg/h IV'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.075 to 0.15 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control in patients with [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIa Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart Rate Control in patients with [[heart failure]] and without [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIa Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg IV each 2 h, up to 1.5 mg''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily IV or orally'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Non-Acute Setting and Chronic Maintenance Therapy'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses; slow release available, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses; slow release available, orally'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart Rate Control in patients with heart failure and without accessory pathway'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 mg by mouth daily''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIb Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''800 mg daily for 1 wk, orally <br> 600 mg daily for 1 wk, orally <br> 400 mg daily for 4 to 6 wk, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''200 mg daily, orally'''''
|-
|-
|}
|}

Revision as of 16:33, 6 March 2014

Drug Loading dose Maintenance dose
Acute Setting
Heart rate control in patients without accessory pathway
▸ Esmolol (Class of recommendation I Level of evidence C) ▸ 500 mcg/kg IV over 1 min ▸ 60 to 200 mcg/kg/min IV
▸ Propanolol (Class of recommendation I Level of evidence C) ▸ 0.15 mg/kg IV ▸ NA
▸ Metoprolol (Class of recommendation I Level of evidence C) ▸ 2.5 to 5 mg IV bolus over 2 min; up to 3 doses ▸ NA
▸ Diltiazem (Class of recommendation I Level of evidence B) ▸ 0.25 mg/kg IV over 2 min ▸ 5 to 15 mg/h IV
▸ Verapamil (Class of recommendation I Level of evidence B) ▸ 0.075 to 0.15 mg/kg IV over 2 min ▸ NA
Heart rate control in patients with accessory pathway
▸ Amiodarone (Class of recommendation IIa Level of evidence C) ▸ 150 mg over 10 min ▸ 0.5 to 1 mg/min IV
Heart Rate Control in patients with heart failure and without accessory pathway
▸ Amiodarone (Class of recommendation IIa Level of evidence C) ▸ 150 mg over 10 min ▸ 0.5 to 1 mg/min IV
▸ Digoxin (Class of recommendation I Level of evidence B) ▸ 0.25 mg IV each 2 h, up to 1.5 mg ▸ 0.125 to 0.375 mg daily IV or orally
Non-Acute Setting and Chronic Maintenance Therapy
Heart rate control
▸ Metoprolol (Class of recommendation I Level of evidence C) ▸ Same as maintenance dose ▸ 25 to 100 mg twice a day, orally
▸ Propanolol (Class of recommendation I Level of evidence C) ▸ Same as maintenance dose ▸ 80 to 240 mg daily in divided doses, orally
▸ Verapamil (Class of recommendation I Level of evidence B) ▸ Same as maintenance dose ▸ 120 to 360 mg daily in divided doses; slow release available, orally
▸ Diltiazem (Class of recommendation I Level of evidence B) ▸ Same as maintenance dose ▸ 120 to 360 mg daily in divided doses; slow release available, orally
Heart Rate Control in patients with heart failure and without accessory pathway
▸ Digoxin (Class of recommendation I Level of evidence B) ▸ 0.5 mg by mouth daily ▸ 0.125 to 0.375 mg daily, orally
▸ Amiodarone (Class of recommendation IIb Level of evidence C) ▸ 800 mg daily for 1 wk, orally
600 mg daily for 1 wk, orally
400 mg daily for 4 to 6 wk, orally		 ▸ 200 mg daily, orally
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_vidit2&oldid=951604"